On March 3, 2025 Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported Dr. Pam Garzone, Chief Development Officer of Anixa, will be attending the Alliance for Cancer Gene Therapy (ACGT) Summit 2025 and participating as a panelist on the Gynecologic and Breast Cancers panel (Press release, Anixa Biosciences, MAR 3, 2025, View Source [SID1234650823]). The Alliance for Cancer Gene Therapy Summit 2025 is being held on Wednesday and Thursday, March 19 – 20, 2025, at the Alexandria Center for Life Science in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Garzone will join leading experts in the field to discuss advancements in cell and gene therapy, including Anixa’s CAR-T therapy for ovarian cancer, and its potential impact on gynecologic and breast cancers. The panel is scheduled for Wednesday, March 19, 2025, from 11:15 AM – 12:15 PM ET.

Dr. Amit Kumar, Chairman and CEO of Anixa, stated, "We are pleased that Anixa and Dr. Garzone were invited to share insights at the ACGT Summit. Our discussions and contributions to the development of novel cancer therapies will help drive meaningful discussions on the future of gene-based treatments for gynecologic and breast cancers."

The Alliance for Cancer Gene Therapy Summit 2025 will bring together leading physician scientists advancing research to develop curative cell and gene therapies for solid tumor cancers.

For more information about the conference, visit Alliance for Gene Therapy Summit 2025.